Studies on Pyrazinoylguanidine

Pharmacology

Volumn 52, Issue 3, 1996, Pages 145-152

  A Rahim, Yousif I ^a   Beyer, Karl H ^a   Vesell, Elliot S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antihyperglycemic drug; Antihyperlipidemic drug; Diabetes mellitus; Hydrochlorothiazide; Metformin; Plasma glucose; Plasma lipids; Pyrazinoylguanidine

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BIGUANIDE; CHOLESTEROL; GLIBENCLAMIDE; GLUCOSE; GUANIDINE DERIVATIVE; LIPID; METFORMIN; PYRAZINOIC ACID; PYRAZINOYLGUANIDINE; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYBURIDE; GUANIDINES; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; MALE; METFORMIN; PYRAZINAMIDE; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 0029993419     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139378     Document Type: Article

References (20)

1. Reavin GM: The fourth Musketeer: From Alexander Dumas to Claude Bernard. Diabetologia 1995:38:3-18.
2. Kahn C: Insulin action, diabeto-genes, and the cause of type II diabetes. Diabetes 1994:43:1066-1084.
3. Brcssler R, Johnson D: New pharmacological approaches to therapy of NIDDM. Diabetes Care 1992;15: 792-805.
4. Williams G: Management of noninsulin-dependent diabetes mellitus. Lancet 1994;343:95-100.
5. Kuusisto J, Mykkanen L. Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-967.
6. Beyer K. Gelarden T: Active transport of urea by mammalian kidney. Proc Natl Acad Sei USA 1988:85: 4030-4031.
7. Beyer K, Gelarden T, Vescll E: Inhibition of urea transport across renal tubules by pyrazinoylguanidine and analogs. Pharmacology 1992:45: 129-141.
8. Beyer K. Ward T, Vary J. Gelarden T, Knutson D, Vesell E: Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiency. J Clin Pharmacol 1993:33:554-561.
9. Chambers C, Vesell E, Helm C. Pas-sananti T, Beyer K: Pyrazinoylguanidine: Antihypertensive, hypo-cholcsterolemic. and renin effects. J Clin Pharmacol 1992:32:1128-1134.
10. Vesell E. Chambers C. Passananti T. Demers L, Beyer K: Effects of pyrazinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insulin-depcn-dent diabetes mellitus. J Clin Pharmacol 1993;33:823-831.
11. Vescll E, Chambers C, DeAngclo S, Passananti T. Demers L, Beyer K: Pyrazinoylguanidine downrcgulatcs the glucose fatty-acid cycle in hypertensive, hyperinsulinemic diabetic patients. J Clin Pharmacol 1994:34: 1234-1245.
12. Like A, Rossini A: Streptozotocin-induced pancreatic insulinitis: New model of diabetes mellitus. Science 1976;193:415-417.
13. Passananti T, Vesell E. Jeszenka E, Gelarden T. Beyer K: Pharmacokinetics of pyrazinoylguanidine. 3-aminopyrazinoylguanidine and their corresponding pyrazinoic acid metabolites in humans and dogs. Pharmacology 1992:45:129-141.
14. Tamasi G, Borsy J. Gypnge R: Changes in scrum triglyceride and cholesterol levels independently of free fatty acids after lipolysis inhibitors. Biochem Pharmacol 1970:19: 1826-1830.
15. Kaijser L, Eklund B, Olsson G, Carlson L: Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979:57:114-117.
16. Groop L: Sulfonylureas in NIDDM. Diabetes Care 1992; 15:737-754.
17. Bailey C: Biguanidcs and NIDDM. Diabetes Care 1992;15:755-772.
18. DeFronzo R, Goodman A. The Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependenl diabetes mellitus. N Engl J Med 1995;333:541-549.
19. Bailey CJ: Metformin: An update. Gen Pharmacol 1993:24:1299-1309.
20. Defronzo R. Barzilai N. Simonson D: Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991:73:1294-1301.